Since both CRYAB and p53 are involved in many aspects of tumorigenesis, CRYAB and p53 co-expression may affect the prognoses of patients with ovarian cancer, which may provide a new targeted therapeutic strategy for ovarian cancer. This evidence concerns the gene TP53 and ovarian cancer.